Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) were down 22.9% on Friday . The company traded as low as C$0.18 and last traded at C$0.19. Approximately 504,239 shares were traded during trading, a decline of 5% from the average daily volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Price Performance
The firm has a market cap of C$28.42 million, a P/E ratio of -5.69 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The stock’s 50-day simple moving average is C$0.19 and its two-hundred day simple moving average is C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Where Do I Find 52-Week Highs and Lows?
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- 3 Warren Buffett Stocks to Buy Now
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- How to Find Undervalued Stocks
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
